Suhua Xia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Suhua Xia has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Tongguo Shi
Jiangsu Institute of Clinical Immunology, the First Affiliated Hospital of Soochow University, Suzhou, China
8 shared publications Haiyan Jin
Jiangsu Institute of Clinical Immunology The First Affiliated Hospital of Soochow University Suzhou China
3 shared publicationsLu Xia
Department of Gastroenterology The First Affiliated Hospital of Soochow University Suzhou China
3 shared publicationsYuqi Chen
Jiangsu Institute of Clinical Immunology The First Affiliated Hospital of Soochow University Suzhou China
3 shared publicationsAnjing Zhao
Jiangsu Institute of Clinical Immunology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215000, China
2 shared publicationsFan Cen
Department of Oncology, The First Affiliated Hospital of Soochow University, Suzhou, China
2 shared publications
Latest Publications
- Open Access
- 27 August 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (9) , 1924
UCHL1 Expression in Colorectal Cancer: Clinicopathological Significance, Prognostic Value, and Implications for Immunotherapy Response
Background/Objectives: Ubiquitin C-terminal hydrolase L1 (UCHL1) exhibits context-dependent roles in various cancers, but its clinical significance and biological functions specifically in colorectal cancer (CRC) remain incompletely understood. Methods: We systematically evaluated UCHL1 expression, clinicopathological associations, prognostic value, and immunological role in CRC using multiple public databases (TCGA, GTEx, UALCAN, GEPIA2, GSCA, and ENCORI) combined with immunohistochemical validation on a tissue microarray containing 80 paired CRC and adjacent normal tissues. Functional enrichment was assessed using ssGSEA, and immune cell infiltration was analyzed using the immunedeconv R package. The immunotherapy response was evaluated using the TIDE algorithm. Results: UCHL1 mRNA and protein levels were significantly downregulated in CRC tissues compared with normal tissues. Paradoxically, high UCHL1 expression was significantly associated with advanced T stage, N stage, TNM stage, and poor overall and disease-free survival. ssGSEA revealed positive associations with multiple aspects of oncogenic pathways, including tumor inflammation signature, tumor proliferation signature, epithelial–mesenchymal transition markers, extracellular matrix-related genes, angiogenesis, apoptosis, and G2M checkpoint regulation. Notably, UCHL1 expression was positively correlated with computationally estimated infiltration of macrophages, CD4+ T cells, and CD8+ T cells, and with elevated expression of immune checkpoint genes, as well as higher TIDE scores. These correlative findings suggest a potential association with immunotherapy-related pathways that warrants further investigation. Conclusions: UCHL1 is downregulated in CRC, but its elevated expression is associated with aggressive disease and poor prognosis. It is implicated in multiple oncogenic pathways and may contribute to an immunosuppressive tumor microenvironment, suggesting its potential as a candidate prognostic biomarker that warrants further functional investigation.
- 27 August 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (9) , 1924
Open AccessUCHL1 Expression in Colorectal Cancer: Clinicopathological Significance, Prognostic Value, and Implications for Immunotherapy Response
Background/Objectives: Ubiquitin C-terminal hydrolase L1 (UCHL1) exhibits context-dependent roles in various cancers, but its clinical significance and biological functions specifically in colorectal cancer (CRC) remain incompletely understood. Methods: We systematically evaluated UCHL1 expression, clinicopathological associations, prognostic value, and immunological role in CRC using multiple public databases (TCGA, GTEx, UALCAN, GEPIA2, GSCA, and ENCORI) combined with immunohistochemical validation on a tissue microarray containing 80 paired CRC and adjacent normal tissues. Functional enrichment was assessed using ssGSEA, and immune cell infiltration was analyzed using the immunedeconv R package. The immunotherapy response was evaluated using the TIDE algorithm. Results: UCHL1 mRNA and protein levels were significantly downregulated in CRC tissues compared with normal tissues. Paradoxically, high UCHL1 expression was significantly associated with advanced T stage, N stage, TNM stage, and poor overall and disease-free survival. ssGSEA revealed positive associations with multiple aspects of oncogenic pathways, including tumor inflammation signature, tumor proliferation signature, epithelial–mesenchymal transition markers, extracellular matrix-related genes, angiogenesis, apoptosis, and G2M checkpoint regulation. Notably, UCHL1 expression was positively correlated with computationally estimated infiltration of macrophages, CD4+ T cells, and CD8+ T cells, and with elevated expression of immune checkpoint genes, as well as higher TIDE scores. These correlative findings suggest a potential association with immunotherapy-related pathways that warrants further investigation. Conclusions: UCHL1 is downregulated in CRC, but its elevated expression is associated with aggressive disease and poor prognosis. It is implicated in multiple oncogenic pathways and may contribute to an immunosuppressive tumor microenvironment, suggesting its potential as a candidate prognostic biomarker that warrants further functional investigation.
- Open Access
- 7 March 2026
- Published by Springer Nature in npj Precision Oncology
- Vol. 10 (1)
AI-enabled single-cell dissection of the palmitoylation landscape identifies a multicellular prognostic program in gastric cancer
Gastric cancer remains highly lethal, yet how protein S-palmitoylation shapes tumour ecosystems and clinical outcome is unclear. We integrated single-cell RNA sequencing (119,931 cells from 25 gastric tumours) with spatial transcriptomics and bulk cohorts to delineate palmitoylation-linked states across malignant, immune, and stromal compartments. A palmitoylation-high malignant programme partitioned into three metastasis-enriched subclusters with increased fatty-acid metabolism and Ras–MAPK signalling and predicted worse survival. Spatial mapping and ligand–receptor inference revealed co-localised niches where palmitoylation-high tumour cells interacted with immunosuppressive myeloid cells and distinct CAF subsets, with strengthened pro-angiogenic and pro-fibrotic cues. We derived and validated an 87-gene multicellular palmitoylation signature for risk stratification, and higher scores were consistently associated with adverse outcomes in external cohorts. Drug-response modelling highlighted vulnerabilities involving the HSP90–PI3K/MAPK axis. Functional assays and xenografts confirmed SH3BGRL as a key driver within this poor-prognosis programme.
- 7 March 2026
- Published by Springer Nature in npj Precision Oncology
- Vol. 10 (1)
Open AccessAI-enabled single-cell dissection of the palmitoylation landscape identifies a multicellular prognostic program in gastric cancer
Gastric cancer remains highly lethal, yet how protein S-palmitoylation shapes tumour ecosystems and clinical outcome is unclear. We integrated single-cell RNA sequencing (119,931 cells from 25 gastric tumours) with spatial transcriptomics and bulk cohorts to delineate palmitoylation-linked states across malignant, immune, and stromal compartments. A palmitoylation-high malignant programme partitioned into three metastasis-enriched subclusters with increased fatty-acid metabolism and Ras–MAPK signalling and predicted worse survival. Spatial mapping and ligand–receptor inference revealed co-localised niches where palmitoylation-high tumour cells interacted with immunosuppressive myeloid cells and distinct CAF subsets, with strengthened pro-angiogenic and pro-fibrotic cues. We derived and validated an 87-gene multicellular palmitoylation signature for risk stratification, and higher scores were consistently associated with adverse outcomes in external cohorts. Drug-response modelling highlighted vulnerabilities involving the HSP90–PI3K/MAPK axis. Functional assays and xenografts confirmed SH3BGRL as a key driver within this poor-prognosis programme.
- Open Access
- 18 November 2025
- Published by Spandidos Publications in Oncology Letters
- Vol. 31 (1) , 1-11
TIMP1 expression in colorectal cancer: Linking prognosis, tumor immunity and molecular pathways
Tissue inhibitor of matrix metalloproteinase 1 (TIMP1) is highly expressed in several cancer types, including lung, brain, prostate, breast and colon cancer, and is associated with a poor prognosis. However, further comprehensive research is required. The present study aimed to explore TIMP1 expression in colorectal cancer (CRC), its prognostic relationship and its connection to tumor immunity, using data from The Cancer Genome Atlas database and clinical samples. The present study evaluated the correlation between TIMP1 expression and CRC by integrating RNA sequencing data, and clinical information from The Cancer Genome Atlas (TCGA), UALCAN and GEPIA2 databases, as well as clinical samples. The findings demonstrated that TIMP1 is highly expressed in CRC tissues and is associated with a poor prognosis. Notably, high TIMP1 levels in CRC were positively correlated with the numbers of CD4+ and CD8+ T cells based on the immune scores, as well as with tumor mutation burden/microsatellite instability. In addition, TIMP1 may be involved in pathways such as those associated with epithelial‑mesenchymal transition, extracellular matrix‑related processes, collagen formation, angiogenesis, apoptosis and ferroptosis. TIMP1 may also be involved in pathways associated with genes upregulated by reactive oxygen species, tumor inflammation and in the TGF‑β signaling pathway. Overall, the results indicate that TIMP1 is associated with prognosis, tumor immunity and several pathways in CRC, potentially offering novel theoretical insights for the treatment of CRC.
- 18 November 2025
- Published by Spandidos Publications in Oncology Letters
- Vol. 31 (1) , 1-11
Open AccessTIMP1 expression in colorectal cancer: Linking prognosis, tumor immunity and molecular pathways
Tissue inhibitor of matrix metalloproteinase 1 (TIMP1) is highly expressed in several cancer types, including lung, brain, prostate, breast and colon cancer, and is associated with a poor prognosis. However, further comprehensive research is required. The present study aimed to explore TIMP1 expression in colorectal cancer (CRC), its prognostic relationship and its connection to tumor immunity, using data from The Cancer Genome Atlas database and clinical samples. The present study evaluated the correlation between TIMP1 expression and CRC by integrating RNA sequencing data, and clinical information from The Cancer Genome Atlas (TCGA), UALCAN and GEPIA2 databases, as well as clinical samples. The findings demonstrated that TIMP1 is highly expressed in CRC tissues and is associated with a poor prognosis. Notably, high TIMP1 levels in CRC were positively correlated with the numbers of CD4+ and CD8+ T cells based on the immune scores, as well as with tumor mutation burden/microsatellite instability. In addition, TIMP1 may be involved in pathways such as those associated with epithelial‑mesenchymal transition, extracellular matrix‑related processes, collagen formation, angiogenesis, apoptosis and ferroptosis. TIMP1 may also be involved in pathways associated with genes upregulated by reactive oxygen species, tumor inflammation and in the TGF‑β signaling pathway. Overall, the results indicate that TIMP1 is associated with prognosis, tumor immunity and several pathways in CRC, potentially offering novel theoretical insights for the treatment of CRC.
- Open Access
- 15 September 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (9) , 2268
Decoding TRIP13’s Role in Gastric Cancer: Implications for Prognosis and Immune Response
Background/Objectives: Gastric cancer (GC), a prevalent global malignancy and a leading cause of cancer-related mortality, has a poorly understood prognosis related to TRIP13 expression. TRIP13 has a recognized part in driving tumor progression across different cancer types, yet its precise role in GC remains beyond our full comprehension. Our study aimed to explore TRIP13’s prognostic value and function in GC patients. Methods: We extensively explored TRIP13’s influence on GC prognosis, functionality, and immune response by examining various cancer-related databases like UALCAN, GEPIA, GEO, and TIMER. Immunohistochemistry (IHC) staining was also conducted to assess the link between TRIM13 and GC patient survival. Results: TRIP13 expression levels were found to be significantly elevated in GC tissues compared to normal tissues through analysis of mRNA data from multiple public databases. IHC analysis exposed elevated TRIP13 protein levels in GC tissues and connected it with tumor depth. Prognostic evaluation demonstrated that GC patients exhibiting heightened TRIP13 expression endured a diminished overall survival rate. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses showed that genes related to TRIP13 are involved in processes such as the cell cycle and DNA repair. Additionally, TRIP13 expression was found to correlate with ferroptosis-related genes and may play a role in regulating ferroptosis. Immune cell infiltration analysis demonstrated that TRIP13 expression is negatively correlated with the infiltration of CD4+ T cells, CD8+ T cells, and B cells. Conclusions: TRIP13 emerges as a candidate independent prognostic indicator and a promising intervention point for GC treatment.
- 15 September 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (9) , 2268
Open AccessDecoding TRIP13’s Role in Gastric Cancer: Implications for Prognosis and Immune Response
Background/Objectives: Gastric cancer (GC), a prevalent global malignancy and a leading cause of cancer-related mortality, has a poorly understood prognosis related to TRIP13 expression. TRIP13 has a recognized part in driving tumor progression across different cancer types, yet its precise role in GC remains beyond our full comprehension. Our study aimed to explore TRIP13’s prognostic value and function in GC patients. Methods: We extensively explored TRIP13’s influence on GC prognosis, functionality, and immune response by examining various cancer-related databases like UALCAN, GEPIA, GEO, and TIMER. Immunohistochemistry (IHC) staining was also conducted to assess the link between TRIM13 and GC patient survival. Results: TRIP13 expression levels were found to be significantly elevated in GC tissues compared to normal tissues through analysis of mRNA data from multiple public databases. IHC analysis exposed elevated TRIP13 protein levels in GC tissues and connected it with tumor depth. Prognostic evaluation demonstrated that GC patients exhibiting heightened TRIP13 expression endured a diminished overall survival rate. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses showed that genes related to TRIP13 are involved in processes such as the cell cycle and DNA repair. Additionally, TRIP13 expression was found to correlate with ferroptosis-related genes and may play a role in regulating ferroptosis. Immune cell infiltration analysis demonstrated that TRIP13 expression is negatively correlated with the infiltration of CD4+ T cells, CD8+ T cells, and B cells. Conclusions: TRIP13 emerges as a candidate independent prognostic indicator and a promising intervention point for GC treatment.
- Open Access
- 29 January 2025
- Published by Elsevier in Translational Oncology
- Vol. 53, 102270
Cellular heterogeneity and communication networks in gastric cancer: Single-cell analysis reveals β-hydroxybutyrylation-associated genes and immune infiltration characteristics
- 29 January 2025
- Published by Elsevier in Translational Oncology
- Vol. 53, 102270
Open AccessCellular heterogeneity and communication networks in gastric cancer: Single-cell analysis reveals β-hydroxybutyrylation-associated genes and immune infiltration characteristics
- Open Access
- 3 September 2023
- Published by Wiley in Cancer Science
- Vol. 114 (11) , 4225-4236
B7H3 increases ferroptosis resistance by inhibiting cholesterol metabolism in colorectal cancer
Ferroptosis, a newly discovered form of regulated cell death, has been reported to be associated with multiple cancers, including colorectal cancer (CRC). However, the underlying molecular mechanism is still unclear. In this study, we identified B7H3 as a potential regulator of ferroptosis resistance in CRC. B7H3 knockdown decreased but B7H3 overexpression increased the ferroptosis resistance of CRC cells, as evidenced by the expression of ferroptosis‐associated genes (PTGS2, FTL, FTH, and GPX4) and the levels of important indicators of ferroptosis (malondialdehyde, iron load). Moreover, B7H3 promoted ferroptosis resistance by regulating sterol regulatory element binding protein 2 (SREBP2)‐mediated cholesterol metabolism. Both exogenous cholesterol supplementation and treatment with the SREBP2 inhibitor betulin reversed the effect of B7H3 on ferroptosis in CRC cells. Furthermore, we verified that B7H3 downregulated SREBP2 expression by activating the AKT pathway. Additionally, multiplex immunohistochemistry was carried out to show the expression of B7H3, prostaglandin‐endoperoxide synthase 2, and SREBP2 in CRC tumor tissues, which was associated with the prognosis of patients with CRC. In summary, our findings reveal a role for B7H3 in regulating ferroptosis by controlling cholesterol metabolism in CRC.
- 3 September 2023
- Published by Wiley in Cancer Science
- Vol. 114 (11) , 4225-4236
Open AccessB7H3 increases ferroptosis resistance by inhibiting cholesterol metabolism in colorectal cancer
Ferroptosis, a newly discovered form of regulated cell death, has been reported to be associated with multiple cancers, including colorectal cancer (CRC). However, the underlying molecular mechanism is still unclear. In this study, we identified B7H3 as a potential regulator of ferroptosis resistance in CRC. B7H3 knockdown decreased but B7H3 overexpression increased the ferroptosis resistance of CRC cells, as evidenced by the expression of ferroptosis‐associated genes (PTGS2, FTL, FTH, and GPX4) and the levels of important indicators of ferroptosis (malondialdehyde, iron load). Moreover, B7H3 promoted ferroptosis resistance by regulating sterol regulatory element binding protein 2 (SREBP2)‐mediated cholesterol metabolism. Both exogenous cholesterol supplementation and treatment with the SREBP2 inhibitor betulin reversed the effect of B7H3 on ferroptosis in CRC cells. Furthermore, we verified that B7H3 downregulated SREBP2 expression by activating the AKT pathway. Additionally, multiplex immunohistochemistry was carried out to show the expression of B7H3, prostaglandin‐endoperoxide synthase 2, and SREBP2 in CRC tumor tissues, which was associated with the prognosis of patients with CRC. In summary, our findings reveal a role for B7H3 in regulating ferroptosis by controlling cholesterol metabolism in CRC.
- Open Access
- 24 July 2023
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 136 (16) , 1977-1989
B7-H3 confers stemness characteristics to gastric cancer cells by promoting glutathione metabolism through AKT/pAKT/Nrf2 pathway
Background: Cancer stem-like cells (CSCs) are a small subset of cells in tumors that exhibit self-renewal and differentiation properties. CSCs play a vital role in tumor formation, progression, relapse, and therapeutic resistance. B7-H3, an immunoregulatory protein, has many protumor functions. However, little is known about the mechanism underlying the role of B7-H3 in regulating gastric cancer (GC) stemness. Our study aimed to explore the impacts of B7-H3 on GC stemness and its underlying mechanism. Methods: GC stemness influenced by B7-H3 was detected both in vitro and in vivo. The expression of stemness-related markers was examined by reverse transcription quantitative polymerase chain reaction, Western blotting, and flow cytometry. Sphere formation assay was used to detect the sphere-forming ability. The underlying regulatory mechanism of B7-H3 on the stemness of GC was investigated by mass spectrometry and subsequent validation experiments. The signaling pathway (Protein kinase B [Akt]/Nuclear factor erythroid 2-related factor 2 [Nrf2] pathway) of B7-H3 on the regulation of glutathione (GSH) metabolism was examined by Western blotting assay. Multi-color immunohistochemistry (mIHC) was used to detect the expression of B7-H3, cluster of differentiation 44 (CD44), and Nrf2 on human GC tissues. Student's t-test was used to compare the difference between two groups. Pearson correlation analysis was used to analyze the relationship between two molecules. The Kaplan–Meier method was used for survival analysis. Results: B7-H3 knockdown suppressed the stemness of GC cells both in vitro and in vivo. Mass spectrometric analysis showed the downregulation of GSH metabolism in short hairpin B7-H3 GC cells, which was further confirmed by the experimental results. Meanwhile, stemness characteristics in B7-H3 overexpressing cells were suppressed after the inhibition of GSH metabolism. Furthermore, Western blotting suggested that B7-H3-induced activation of GSH metabolism occurred through the AKT/Nrf2 pathway, and inhibition of AKT signaling pathway could suppress not only GSH metabolism but also GC stemness. mIHC showed that B7-H3 was highly expressed in GC tissues and was positively correlated with the expression of CD44 and Nrf2. Importantly, GC patients with high expression of B7-H3, CD44, and Nrf2 had worse prognosis (P = 0.02). Conclusions: B7-H3 has a regulatory effect on GC stemness and the regulatory effect is achieved through the AKT/Nrf2/GSH pathway. Inhibiting B7-H3 expression may be a new therapeutic strategy against GC.
- 24 July 2023
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 136 (16) , 1977-1989
Open AccessB7-H3 confers stemness characteristics to gastric cancer cells by promoting glutathione metabolism through AKT/pAKT/Nrf2 pathway
Background: Cancer stem-like cells (CSCs) are a small subset of cells in tumors that exhibit self-renewal and differentiation properties. CSCs play a vital role in tumor formation, progression, relapse, and therapeutic resistance. B7-H3, an immunoregulatory protein, has many protumor functions. However, little is known about the mechanism underlying the role of B7-H3 in regulating gastric cancer (GC) stemness. Our study aimed to explore the impacts of B7-H3 on GC stemness and its underlying mechanism. Methods: GC stemness influenced by B7-H3 was detected both in vitro and in vivo. The expression of stemness-related markers was examined by reverse transcription quantitative polymerase chain reaction, Western blotting, and flow cytometry. Sphere formation assay was used to detect the sphere-forming ability. The underlying regulatory mechanism of B7-H3 on the stemness of GC was investigated by mass spectrometry and subsequent validation experiments. The signaling pathway (Protein kinase B [Akt]/Nuclear factor erythroid 2-related factor 2 [Nrf2] pathway) of B7-H3 on the regulation of glutathione (GSH) metabolism was examined by Western blotting assay. Multi-color immunohistochemistry (mIHC) was used to detect the expression of B7-H3, cluster of differentiation 44 (CD44), and Nrf2 on human GC tissues. Student's t-test was used to compare the difference between two groups. Pearson correlation analysis was used to analyze the relationship between two molecules. The Kaplan–Meier method was used for survival analysis. Results: B7-H3 knockdown suppressed the stemness of GC cells both in vitro and in vivo. Mass spectrometric analysis showed the downregulation of GSH metabolism in short hairpin B7-H3 GC cells, which was further confirmed by the experimental results. Meanwhile, stemness characteristics in B7-H3 overexpressing cells were suppressed after the inhibition of GSH metabolism. Furthermore, Western blotting suggested that B7-H3-induced activation of GSH metabolism occurred through the AKT/Nrf2 pathway, and inhibition of AKT signaling pathway could suppress not only GSH metabolism but also GC stemness. mIHC showed that B7-H3 was highly expressed in GC tissues and was positively correlated with the expression of CD44 and Nrf2. Importantly, GC patients with high expression of B7-H3, CD44, and Nrf2 had worse prognosis (P = 0.02). Conclusions: B7-H3 has a regulatory effect on GC stemness and the regulatory effect is achieved through the AKT/Nrf2/GSH pathway. Inhibiting B7-H3 expression may be a new therapeutic strategy against GC.
- 10 February 2022
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 477 (5) , 1371-1380
The potential roles and mechanisms of non-coding RNAs in cancer anoikis resistance
Increasing evidence indicates that anoikis resistance is a critical process for metastasis of cancer cells, making it the attractive therapeutic target for cancer benefit. Anoikis resistance is widely regulated by various factors, such as signaling pathways, integrins switch, and non-coding RNAs (ncRNAs). ncRNAs composed of microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs), are frequently dysregulated in a variety of human malignancies and are closely related to anoikis resistance of cancer cells. Based on the available literature, we reviewed the molecular basis underlying ncRNAs modulating cancer cells anoikis resistance, which may contribute to a better understanding of cancer metastasis and provide new beneficial therapeutic strategies against cancer.
- 10 February 2022
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 477 (5) , 1371-1380
The potential roles and mechanisms of non-coding RNAs in cancer anoikis resistance
Increasing evidence indicates that anoikis resistance is a critical process for metastasis of cancer cells, making it the attractive therapeutic target for cancer benefit. Anoikis resistance is widely regulated by various factors, such as signaling pathways, integrins switch, and non-coding RNAs (ncRNAs). ncRNAs composed of microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs), are frequently dysregulated in a variety of human malignancies and are closely related to anoikis resistance of cancer cells. Based on the available literature, we reviewed the molecular basis underlying ncRNAs modulating cancer cells anoikis resistance, which may contribute to a better understanding of cancer metastasis and provide new beneficial therapeutic strategies against cancer.
- Open Access
- 18 September 2021
- Published by Springer Nature in Cell Death Discovery
- Vol. 7 (1) , 1-8
B7-H5 blockade enhances CD8+ T-cell-mediated antitumor immunity in colorectal cancer
Negative immune checkpoint blockade immunotherapy has shown potential for multiple malignancies including colorectal cancer (CRC). B7-H5, a novel negative immune checkpoint regulator, is highly expressed in tumor tissues and promotes tumor immune escape. However, the clinical significance of B7-H5 expression in CRC and the role of B7-H5 in the tumor microenvironment (TME) has not been fully clarified. In this study, we observed that high B7-H5 expression in CRC tissues was significantly correlated with the lymph node involvement, AJCC stage, and survival of CRC patients. A significant inverse correlation was also observed between B7-H5 expression and CD8+ T-cell infiltration in CRC tissues. Kaplan−Meier analysis showed that patients with high B7-H5 expression and low CD8+ T-cell infiltration had the worst prognosis in our cohort of CRC patients. Remarkably, both high B7-H5 expression and low CD8+ T infiltration were risk factors for overall survival. Additionally, B7-H5 blockade using a B7-H5 monoclonal antibody (B7-H5 mAb) effectively suppressed the growth of MC38 colon cancer tumors by enhancing the infiltration and Granzyme B production of CD8+ T cells. Importantly, the depletion of CD8+ T cells obviously abolished the antitumor effect of B7-H5 blockade in the MC38 tumors. In sum, our findings suggest that B7-H5 may be a valuably prognostic marker for CRC and a potential target for CRC immunotherapy.
- 18 September 2021
- Published by Springer Nature in Cell Death Discovery
- Vol. 7 (1) , 1-8
Open AccessB7-H5 blockade enhances CD8+ T-cell-mediated antitumor immunity in colorectal cancer
Negative immune checkpoint blockade immunotherapy has shown potential for multiple malignancies including colorectal cancer (CRC). B7-H5, a novel negative immune checkpoint regulator, is highly expressed in tumor tissues and promotes tumor immune escape. However, the clinical significance of B7-H5 expression in CRC and the role of B7-H5 in the tumor microenvironment (TME) has not been fully clarified. In this study, we observed that high B7-H5 expression in CRC tissues was significantly correlated with the lymph node involvement, AJCC stage, and survival of CRC patients. A significant inverse correlation was also observed between B7-H5 expression and CD8+ T-cell infiltration in CRC tissues. Kaplan−Meier analysis showed that patients with high B7-H5 expression and low CD8+ T-cell infiltration had the worst prognosis in our cohort of CRC patients. Remarkably, both high B7-H5 expression and low CD8+ T infiltration were risk factors for overall survival. Additionally, B7-H5 blockade using a B7-H5 monoclonal antibody (B7-H5 mAb) effectively suppressed the growth of MC38 colon cancer tumors by enhancing the infiltration and Granzyme B production of CD8+ T cells. Importantly, the depletion of CD8+ T cells obviously abolished the antitumor effect of B7-H5 blockade in the MC38 tumors. In sum, our findings suggest that B7-H5 may be a valuably prognostic marker for CRC and a potential target for CRC immunotherapy.